# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Booker T. Washington (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI017-SYN-TD
- Date: 1915-05-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Whitfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for primary care visit for headaches, fatigue, and a very high blood pressure. **S**

## Objective

Sodium: 139 mmol/L; Potassium: 4.4 mmol/L; Bicarbonate (total CO2): 21 mmol/L (low); BUN: 34 mg/dL (high); Creatinine: 2.1 mg/dL (high); eGFR: 36 mL/min/1.73 m² (low); Glucose: 92 mg/dL; Calcium: 9.1 mg/dL; Phosphate: 4.2 mg/dL; Intact PTH: 92 pg/mL (high); Hemoglobin: 12.6 g/dL (low); Ferritin: 210 ng/mL; Transferrin saturation: 26%; TSH: 1.8 mIU/L; HbA1c: 5.4%; LDL cholesterol: 138 mg/dL (high); Urine albumin-creatinine ratio: 820 mg/g (high); PHQ-9: 4. All results are synthetic.

BP 212/128 mmHg; pulse 88 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 97% on room air; weight 71 kg; BMI 24.6 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1804 blood pressure of 220/150; Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosis; Hypertensive retinopathy, both eyes, without papilledema; Mild anemia of chronic kidney disease, iron replete; monitor; Hyperlipidemia. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Amlodipine 10 mg oral tablet, one tablet by mouth daily **S**
- Started: Losartan 50 mg oral tablet, one tablet by mouth daily **S**
- Started: Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Plan

- Treat severe hypertension without acute target-organ damage as an outpatient: start losartan and amlodipine together, check home blood pressure twice daily, and go to the emergency department for chest pain, shortness of breath, weakness, confusion, or vision loss. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025) **S**
- Nephrology referral for eGFR below 60 with severely increased albuminuria (UACR above 300 mg/g) and stage 2 hypertension. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026) **S**
- Titrate losartan to the maximum tolerated dose and add an SGLT2 inhibitor for CKD with UACR of at least 200 mg/g; accept a creatinine rise of up to 30 percent. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021) **S**
- Check potassium and creatinine one to four weeks after each renin-angiotensin, SGLT2 inhibitor, or diuretic change; then eGFR and UACR about three times a year for G3b A3, hemoglobin at least yearly, and calcium, phosphate, and PTH every six to twelve months; recalculate the kidney failure risk yearly. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026) **S**
- Moderate-intensity statin for an adult aged 50 or older with eGFR below 60; no routine repeat LDL. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026) **S**
- Sodium below 2 g a day with a plan for meals while traveling; at least 150 minutes of activity a week. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Annual dilated eye examination for hypertensive retinopathy; pneumococcal and hepatitis B vaccination for chronic kidney disease. Guideline: CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026) **S**
